Announcing New Clinical Trials

[Anonymous]

Birinapant Trial in Phase II for Higher-Risk Newly Diagnosed MDS/CMML Patients – A clinical research study sponsored by TetraLogic Pharmaceutical Corporation. This is a study of azacitidine with and without the experimental drug birinapant (TL32711) for those who have higher-risk MDS or CMML who are naïve to azacitidine therapy. This is a global trial with sites across Spain, Germany and Australia taking part in the last Quarter of 2014. Accrual of patients is ongoing in US. https://clinicaltrials.gov/ct2/show/NCT02147873

ASTX727 Clinical Trial for Low to High-Risk MDS/CMML Patients – Astex Pharmaceuticals is conducting a Phase 1-2 clinical trial to determine if ASTX727 is effective for the treatment of patients with IPSS low, intermediate -1, intermediate -2, or high risk MDS (including CMML). https://clinicaltrials.gov/ct2/show/NCT02103478

QUAZAR Study for Lower-Risk MDS Patients – A clinical research trial sponsored by Celgene Corporation. This is a study for people with MDS who need blood transfusions due to low red blood cell counts (called anemia) and low platelet counts (called thrombocytopenia). https://www.celgeneclinicaltrials.com/quazar-mds

• This topic was modified 9 years, 2 months ago by .

[Author]

Posts